Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 15:12:44 UTC |
---|
Update Date | 2022-03-07 02:49:18 UTC |
---|
HMDB ID | HMDB0003252 |
---|
Secondary Accession Numbers | - HMDB0005070
- HMDB03252
- HMDB05070
|
---|
Metabolite Identification |
---|
Common Name | Thromboxane B2 |
---|
Description | Thromboxanes. A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). -- Pubchem. Thromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
---|
Structure | CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O InChI=1S/C20H34O6/c1-2-3-6-9-15(21)12-13-18-16(17(22)14-20(25)26-18)10-7-4-5-8-11-19(23)24/h4,7,12-13,15-18,20-22,25H,2-3,5-6,8-11,14H2,1H3,(H,23,24)/b7-4-,13-12+/t15-,16-,17-,18+,20?/m0/s1 |
---|
Synonyms | Value | Source |
---|
TXB2 | ChEBI | b2, Thromboxane | HMDB |
|
---|
Chemical Formula | C20H34O6 |
---|
Average Molecular Weight | 370.4804 |
---|
Monoisotopic Molecular Weight | 370.23553882 |
---|
IUPAC Name | (5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoic acid |
---|
Traditional Name | thromboxane B2 |
---|
CAS Registry Number | 54397-85-2 |
---|
SMILES | CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O |
---|
InChI Identifier | InChI=1S/C20H34O6/c1-2-3-6-9-15(21)12-13-18-16(17(22)14-20(25)26-18)10-7-4-5-8-11-19(23)24/h4,7,12-13,15-18,20-22,25H,2-3,5-6,8-11,14H2,1H3,(H,23,24)/b7-4-,13-12+/t15-,16-,17-,18+,20?/m0/s1 |
---|
InChI Key | XNRNNGPBEPRNAR-JQBLCGNGSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as thromboxanes. These are eicosanoids structurally characterized by the presence of a 6-member ether containing ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Thromboxanes |
---|
Alternative Parents | |
---|
Substituents | - Thromboxane
- Long-chain fatty acid
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Fatty acid
- Oxane
- Unsaturated fatty acid
- Hemiacetal
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Oxacycle
- Monocarboxylic acid or derivatives
- Organoheterocyclic compound
- Organic oxide
- Organic oxygen compound
- Hydrocarbon derivative
- Carbonyl group
- Alcohol
- Organooxygen compound
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Thromboxane B2,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2957.6 | Semi standard non polar | 33892256 | Thromboxane B2,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O | 2907.8 | Semi standard non polar | 33892256 | Thromboxane B2,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 2858.9 | Semi standard non polar | 33892256 | Thromboxane B2,1TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2915.2 | Semi standard non polar | 33892256 | Thromboxane B2,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2909.8 | Semi standard non polar | 33892256 | Thromboxane B2,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2850.6 | Semi standard non polar | 33892256 | Thromboxane B2,2TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2908.5 | Semi standard non polar | 33892256 | Thromboxane B2,2TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 2873.6 | Semi standard non polar | 33892256 | Thromboxane B2,2TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2875.2 | Semi standard non polar | 33892256 | Thromboxane B2,2TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2839.1 | Semi standard non polar | 33892256 | Thromboxane B2,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2842.9 | Semi standard non polar | 33892256 | Thromboxane B2,3TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2860.0 | Semi standard non polar | 33892256 | Thromboxane B2,3TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2818.5 | Semi standard non polar | 33892256 | Thromboxane B2,3TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2832.6 | Semi standard non polar | 33892256 | Thromboxane B2,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2827.1 | Semi standard non polar | 33892256 | Thromboxane B2,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3201.8 | Semi standard non polar | 33892256 | Thromboxane B2,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O | 3111.5 | Semi standard non polar | 33892256 | Thromboxane B2,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 3072.0 | Semi standard non polar | 33892256 | Thromboxane B2,1TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3171.0 | Semi standard non polar | 33892256 | Thromboxane B2,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3356.0 | Semi standard non polar | 33892256 | Thromboxane B2,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3322.3 | Semi standard non polar | 33892256 | Thromboxane B2,2TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3425.0 | Semi standard non polar | 33892256 | Thromboxane B2,2TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 3301.2 | Semi standard non polar | 33892256 | Thromboxane B2,2TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3338.2 | Semi standard non polar | 33892256 | Thromboxane B2,2TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3310.4 | Semi standard non polar | 33892256 | Thromboxane B2,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3509.5 | Semi standard non polar | 33892256 | Thromboxane B2,3TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3559.7 | Semi standard non polar | 33892256 | Thromboxane B2,3TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1OC(O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3532.5 | Semi standard non polar | 33892256 | Thromboxane B2,3TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3509.1 | Semi standard non polar | 33892256 | Thromboxane B2,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3676.6 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Thromboxane B2 GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f6y-8898000000-de2ae12c86f74eb4a1f3 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thromboxane B2 GC-MS (4 TMS) - 70eV, Positive | splash10-00kf-4500079000-16f7d857bfedfb2b9ef2 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thromboxane B2 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-014i-0911000000-8bc209cb114bb1917b0d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-016r-0910000000-7e2600e44fee0ea8636e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-014i-0910000000-071d732845973c921ada | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-014i-0920000000-457ff2b2fc3e77dae9c6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-016r-0900000000-949c205efe6ebe79cc8f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-014i-0900000000-58c0038e67eb610af9dc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-014i-0900000000-78022e9724d72fe03fc6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-014i-2900000000-6141a0015f32b8b88e41 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thromboxane B2 LC-ESI-QIT , negative-QTOF | splash10-0690-0900000000-3fc1a2ec184afc048db2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 10V, Positive-QTOF | splash10-0f79-0239000000-9a9e5b4d919679eec445 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 20V, Positive-QTOF | splash10-0f79-2149000000-4330663714a6c7a5c3c1 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 40V, Positive-QTOF | splash10-06du-9210000000-96175166f5a2af4d2062 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 10V, Negative-QTOF | splash10-016s-0069000000-42550c760b9ebada3323 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 20V, Negative-QTOF | splash10-11os-3598000000-e17f85b6dd865184b89f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 40V, Negative-QTOF | splash10-0a4i-9541000000-f13713eefad69561b2d8 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 10V, Positive-QTOF | splash10-0udr-0009000000-e9a9bf86af8ea88c1ed9 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 20V, Positive-QTOF | splash10-0k9m-9314000000-acb8a81c85f0c0eeb2c3 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 40V, Positive-QTOF | splash10-0aor-9400000000-824736787ce880eeebaf | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 10V, Negative-QTOF | splash10-014i-0009000000-93e9a6bd1728415ca7e1 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 20V, Negative-QTOF | splash10-014i-1049000000-e337054bfdddde89caaa | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane B2 40V, Negative-QTOF | splash10-05mp-7191000000-c2285e7becd7a28a17fb | 2021-09-23 | Wishart Lab | View Spectrum |
|
---|
Disease References | Ischemic heart disease |
---|
- Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P: Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006 Sep;80(3):264-74. [PubMed:16952493 ]
| Brain tumors |
---|
- Walker V, Pickard JD, Smythe PJ, Perry S: Eicosanoid production by brain tumours in vivo--evidence for intracranial compartmentation. J Neurooncol. 1991 Dec;11(3):259-62. [PubMed:1823345 ]
| Hydrocephalus |
---|
- Westcott JY, Murphy RC, Stenmark K: Eicosanoids in human ventricular cerebrospinal fluid following severe brain injury. Prostaglandins. 1987 Dec;34(6):877-87. [PubMed:2835791 ]
| Ischemia |
---|
- Westcott JY, Murphy RC, Stenmark K: Eicosanoids in human ventricular cerebrospinal fluid following severe brain injury. Prostaglandins. 1987 Dec;34(6):877-87. [PubMed:2835791 ]
| Meningitis |
---|
- Westcott JY, Murphy RC, Stenmark K: Eicosanoids in human ventricular cerebrospinal fluid following severe brain injury. Prostaglandins. 1987 Dec;34(6):877-87. [PubMed:2835791 ]
|
|
---|
General References | - Laitinen O, Seppala E, Nissila M, Vapaatalo H: Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis. Clin Rheumatol. 1983 Dec;2(4):401-6. [PubMed:6589104 ]
- Janssen PL, Meyboom S, van Staveren WA, de Vegt F, Katan MB: Consumption of ginger (Zingiber officinale roscoe) does not affect ex vivo platelet thromboxane production in humans. Eur J Clin Nutr. 1996 Nov;50(11):772-4. [PubMed:8933126 ]
- Turi S, Bereczki C, Torday C, Havass Z, Nemeth M: The effects of bicarbonate and acetate haemodialysis on platelet cyclic AMP concentration, thromboxane B2 release and aggregation. Pediatr Nephrol. 1991 May;5(3):327-31. [PubMed:1651098 ]
- Vissinger H, Husted SE, Kristensen SD, Nielsen HK: Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid. Angiology. 1993 Aug;44(8):633-8. [PubMed:8342880 ]
- Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM: Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta. 1996 Mar 15;246(1-2):163-82. [PubMed:8814965 ]
- Zahavi M, Zahavi J: Concomitant in vitro platelet hypofunction and increased thromboxane B2 (TXB2) generation and enhanced in vivo platelet activation. A distinct syndrome in thrombosis? Eur J Haematol. 1997 Oct;59(4):266-7. [PubMed:9338626 ]
- Nyyssonen K, Seppanen K, Salonen JT: High-performance liquid chromatographic assay of platelet-produced thromboxane B2. J Chromatogr. 1993 Jan 29;612(1):27-32. [PubMed:8454699 ]
- Anfossi G, Trovati M, Mularoni E, Massucco P, Cavalot F, Mattiello L, Emanuelli G: Effects of diltiazem on thromboxane B2 production from platelet-rich plasma and whole blood. Prostaglandins Leukot Essent Fatty Acids. 1991 Nov;44(3):149-54. [PubMed:1808624 ]
- Fuse S, Tomita H, Chiba S: Plasma thromboxane B2 concentration in patients with ventricular septal defect and pulmonary hypertension. Jpn Circ J. 1998 Mar;62(3):193-7. [PubMed:9583446 ]
- Tewes KS, Tsikas D, Gutzki FM, Frolich JC: Measurement of thromboxane B2 in platelet-rich human plasma by gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry following extractive pentafluorobenzyl esterification. Anal Biochem. 1998 Jul 15;261(1):121-4. [PubMed:9683522 ]
- de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I: Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther. 1999 Oct;66(4):425-30. [PubMed:10546927 ]
- Mistakopulo NF, Shoshiashvili VD, Saltanov AI, Kushlinskii NE, Ivshina AV, Madzhuga AI, Liakina LT, Ukrainets AM, Zabotina TN, Kadagidze ZG: [The effect of indomethacin and leukinferon on the level of blood plasma thromboxane B2, platelet aggregation and the immune system of patients with endometrial cancer in the perioperative period]. Anesteziol Reanimatol. 1992 Mar-Apr;(2):14-8. [PubMed:1416192 ]
- Fuse S, Kamiya T: Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation. 1994 Dec;90(6):2952-5. [PubMed:7994842 ]
|
---|